BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 14595509)

  • 61. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens?
    Momeni M; Kolev V; Cardenas-Goicoechea J; Getrajdman J; Fishman D; Chuang L; Kalir T; Rahaman J; Zakashansky K
    Am J Obstet Gynecol; 2013 Jan; 208(1):71.e1-6. PubMed ID: 23099190
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A 14-year-old female patient with FIGO stage IB endometrial carcinoma: a case report.
    Mitamura T; Watari H; Todo Y; Koshida T; Sakuragi N
    Int J Gynecol Cancer; 2009 Jul; 19(5):896-7. PubMed ID: 19574781
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Expression of tubulin, p53, ki67, receptors for estrogen, and progesterone in endometrial cancer.
    Zhu C; Luo J; Shi H; Xie X; Ding Z
    Eur J Gynaecol Oncol; 2009; 30(5):514-7. PubMed ID: 19899405
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
    Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
    Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
    Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
    Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
    Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
    Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.
    Jongen VH; Briët JM; de Jong RA; Joppe E; ten Hoor KA; Boezen HM; Evans DB; Hollema H; van der Zee AG; Nijman HW
    Int J Gynecol Cancer; 2009 May; 19(4):670-6. PubMed ID: 19509570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas.
    Gul AE; Keser SH; Barisik NO; Kandemir NO; Cakir C; Sensu S; Karadayi N
    Diagn Pathol; 2010 Feb; 5():13. PubMed ID: 20167054
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
    Reynaers EA; Ezendam NP; Pijnenborg JM
    J Surg Oncol; 2015 May; 111(6):790-4. PubMed ID: 25900897
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H
    PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668
    [TBL] [Abstract][Full Text] [Related]  

  • 72. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
    Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
    Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
    [TBL] [Abstract][Full Text] [Related]  

  • 74. P53 and BCL-2 as prognostic markers in endometrial carcinoma.
    Appel ML; Edelweiss MI; Fleck J; Rivero LF; Rivoire WA; Mônego HI; Dos Reis R
    Pathol Oncol Res; 2008 Mar; 14(1):23-30. PubMed ID: 18398703
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preoperative MRI and intraoperative frozen section diagnosis of myometrial invasion in patients with endometrial cancer.
    Tanaka T; Terai Y; Ono YJ; Fujiwara S; Tanaka Y; Sasaki H; Tsunetoh S; Kanemura M; Yamamoto K; Yamada T; Ohmichi M
    Int J Gynecol Cancer; 2015 Jun; 25(5):879-83. PubMed ID: 25950131
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
    González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
    Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Köbel M; Atenafu EG; Rambau PF; Ferguson SE; Nelson GS; Ho TC; Panzarella T; McAlpine JN; Gilks CB; Clarke BA; Bernardini MQ
    Gynecol Oncol; 2016 Jun; 141(3):559-563. PubMed ID: 27072807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Possibility of PTEN expression on predicting pathologic risk factors of endometrioid adenocarcinoma before operation].
    Lou HY; Lin kQ; Ye DF; Xie X; Yu X
    Ai Zheng; 2005 Jun; 24(6):748-50. PubMed ID: 15946494
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
    Hu WF; Liu MQ; Zhao Q
    Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination analysis of Bub1 and Mad2 expression in endometrial cancer: act as a prognostic factor in endometrial cancer.
    Li L; Xu DB; Zhao XL; Hao TY
    Arch Gynecol Obstet; 2013 Jul; 288(1):155-65. PubMed ID: 23334889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.